Cidara Therapeutics (CDTX)
(Real Time Quote from BATS)
$11.18 USD
-0.09 (-0.80%)
Updated Sep 23, 2024 02:12 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Cidara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 64 | 64 | 50 | 12 | 21 |
Cost Of Goods | 2 | 0 | 0 | 0 | 0 |
Gross Profit | 62 | 64 | 50 | 12 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 87 | 94 | 92 | 84 | 63 |
Income After Depreciation & Amortization | -24 | -30 | -42 | -72 | -42 |
Non-Operating Income | 2 | 0 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -22 | -30 | -42 | -72 | -41 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -23 | -30 | -42 | -72 | -41 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -23 | -30 | -42 | -72 | -41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -28 | -43 | -72 | -41 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | -1 | 0 | 0 |
Income After Depreciation & Amortization | -24 | -30 | -42 | -72 | -42 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.37 | 3.49 | 2.62 | 2.08 | 1.46 |
Diluted EPS Before Non-Recurring Items | -5.20 | -8.60 | -16.20 | -36.00 | -28.20 |
Diluted Net EPS (GAAP) | -5.20 | -8.60 | -16.20 | -36.00 | -28.20 |
Fiscal Year end for Cidara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.30 | 8.46 | 17.58 | 12.72 | 7.61 |
Cost Of Goods | 0.00 | 1.56 | 1.14 | 0.39 | 0.00 |
Gross Profit | 0.30 | 6.90 | 16.45 | 12.33 | 7.61 |
SG&A, R&D, and Dept/Amort Expenses | 96.29 | 17.59 | 22.52 | 20.89 | 20.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | -95.99 | -10.69 | -6.07 | -8.56 | -12.84 |
Non-Operating Income | 1.77 | 0.37 | 0.76 | 0.61 | 0.62 |
Interest Expense | 0.00 | 0.00 | 0.23 | 0.00 | 0.00 |
Pretax Income | -94.21 | -10.33 | -5.55 | -7.94 | -12.21 |
Income Taxes | 0.00 | 0.00 | 0.06 | 0.23 | 0.15 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -94.21 | -10.33 | -5.61 | -8.17 | -12.36 |
Extras & Discontinued Operations | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -91.21 | -10.33 | -5.61 | -8.17 | -12.36 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.56 | 4.54 | 4.53 | 4.51 | 4.51 |
Diluted EPS Before Non-Recurring Items | -2.05 | -2.28 | -0.80 | -1.80 | -2.80 |
Diluted Net EPS (GAAP) | -19.99 | -2.28 | -1.20 | -1.80 | -2.80 |